Skip to main content
. Author manuscript; available in PMC: 2016 Aug 22.
Published in final edited form as: Cancer. 2010 Aug 15;116(16):3852–3861. doi: 10.1002/cncr.25123

Table 2.

Best Hematologic and Cytogenetic Responses

CML in Myeloid Blast
Phase
CML in Lymphoid Blast
Phase
Response Dasatinib
140 mg QD
Dasatinib
70 mg BID
Dasatinib
140 mg QD
Dasatinib
70 mg BID
Hematologic response
  No. of patients n¼75 n¼74 n¼33 n¼28
  MHR, n (%) 21 (28) 21 (28) 14 (42) 9 (32)
    95% CI 18–40 19–40 26–61 16–52
    Median time to MHR [95%CI], moa 2 [1.8–2.8] 3 [1.5–2.8] 2 [1.0–1.8] 2 [1.2–3.0]
    Median duration of MHR [95% CI], moa 8 [5.6–20.7] 9 [7.1-NA] 5 [4.0–8.1] 8 [7.1–9.9]
  Any BCR-ABL mutation, n/total (%) 9/32 (28) 9/28 (32) 7/20 (35) 4/14 (29)
  No mutation, n/total (%) 10/33 (30) 10/36 (28) 3/9 (33) 2/7 (29)
  Complete hematologic response, n (%) 13 (17) 13 (18) 7 (21) 4 (14)
  No evidence of leukemia, n (%) 8 (11) 8 (11) 7 (21) 5 (18)
Cytogenetic responseb
  No. of patients n¼72 n¼71 n¼32 n¼25
  MCyR, n (%) 18 (25) 20 (28) 16 (50) 10 (40)
    95% CI 16–37 18–40 32–68 21–61
    Median time to MCyR [95%CI], moa 1.9 [1.4–2.8] 1.6 [1.0–2.8] 1.4 [1.0–1.9] 1.4 [1.1–1.9]
    Median duration of MCyR [95%CI], moa 7.7 [4.7–13.1] 10.1 [7.3-NA] 4.0 [3.0–6.3] 7.0 [2.0–10.5]
  CCyR, n (%) 10 (14) 15 (21) 12 (38) 9 (36)
    Median time to CCyR [95% CI], moa 2.1 [1.8–2.8] 2.8 [1.7–3.6] 1.8 [1.0–1.9] 1.4 [1.1–1.9]
    Median duration of CCyR [95% CI], moa NR [3.7-NA] 7.4 [7.1-NA] 4.9 [3.9–6.3] 7.9 [3.7–10.5]

CML indicates chronic myeloid leukemia; QD, once daily; BID, twice daily; MHR, major hematologic response; CI, confidence interval; BCR-ABL, breakpoint cluster region-Abelson murine leukemia viral oncogene fusion protein; NA, not available; MCyR, major cytogenetic response; CCyR, complete cytogenetic response; NR, not reached.

a

Computed from Kaplan-Meier analysis in patients who achieved this response.

b

The analysis excluded 10 Philadelphia chromosome-negative patients. Cytogenetic response could not be determined among patients with CML in myeloid blast phase for 22 patients in the QD arm and 23 patients in the BID arm or among patients with CML in lymphoid blast phase for 8 patients in the QD arm and 9 patients in the BID arm.